Objectives: To evaluate whether early canakinumab initiation may provide treatment advantages in Still’s disease (SD) patients, particularly in terms of therapy discontinuation due to long-term disease remission, glucocorticoid sparing effect, and increase in the frequency of monocyclic disease course rather than a polycyclic or chronic articular pattern. Methods: SD patients treated with canakinumab were grouped according to time between disease onset and canakinumab initiation (≤3 months vs. >3 months). Patients were enrolled from the international AutoInflammatory Disease Alliance (AIDA) Network registry for SD. Results: Overall, 190 patients were enrolled, 35 (19%) treated with canakinumab within three months from SD onset and 155 (82%) starting canakinumab later. Glucocorticoids use decreased more rapidly in patients receiving canakinumab within 3 months from SD onset than among patients treated later, with reductions of 50% vs 6% at month 3 (p=0.0001), and 75% vs 32% at month 6 (p=0.004). In logistic regression analysis, canakinumab initiation within 3 months from disease onset was significantly associated with treatment discontinuation due to long-term remission (OR 4.83, 95% CI 1.08-23.19; p=0.04). A monocyclic course occurred in 49% of patients starting canakinumab ≤3 months versus 8% starting later (p<0.0001). Starting canakinumab within 3 months from disease onset was significantly associated with a monocyclic disease course compared with the chronic-articular (RRR 4.43, 95% CI 1.12-17.60; p=0.034) and polycyclic courses (RRR 8.97, 95% CI 1.29-62.3; p=0.03). Conclusions: Early canakinumab initiation is associated with treatment discontinuation due to long-term remission and appears linked to a greater frequency of a monocyclic disease course.
444., V. A., Caggiano, V., Sbalchiero, J., Lopalco, G., Tufan, A., Ragab, G., Sfikakis, P., Dagna, L., Batu, E., Ozen, S., Conti, F., Maiolini, F., Bugatti, S., Frassi, M., Ruscitti, P., Cito, A., Cakir, I., Akay, N., Konte, E., Laskari, K., Emreol, H., Priori, R., Croce, J., De Stefano, L., Francesca, C., Cipriani, P., La Torre, F., Maggio, M., Al-Mayouf, S., Fotis, L., Rigante, D., Verrecchia, E., Guggino, G., La Barbera, L., Piga, M., Emmi, G., Gallizzi, R., Conti, G., Sfriso, P., Bartoloni, E., Giacomelli, R., Barone, P., Gicchino, M., Alemanno, A., Gullo, A., Direskeneli, H., Alibaz-Oner, F., Karamanakos, A., Prete, M., Edrees, A., Gavioli, F., Parronchi, P., Ciccia, F., Cardamone, C., Hernández-Rodríguez, J., Hatemi, G., Bes, C., Almaghlouth, I., Marhuenda, Á., Gonzáles-García, A., Gaggiano, C., Mormile, I., Tezcan, M., Brucato, A., Feist, E., Tornero-Romero, F., Suzon, B., Ogunjimi, B., Thabet, M., Conforti, A., Pucino, V., Boyarchuk, O., Kovalchuk, T., Govoni, M., Iagnocco, A., Chimenti, M., Moshrif, A., Giudice, E., Carubbi, F., Erten, Ş., Tharwat, S., Hegazy, M., Więsik-Szewczyk, E., Torres-Ruiz, J., Martín-Nares, E., Balistreri, A., Fabiani, C., Frediani, B., Hinojosa-Azaola, A., Kasapçopur, Ö., Cantarini, L., Long-term remission and monocyclic course in Still’s disease patients starting canakinumab early: data from the international AIDA Network registry, <<SEMINARS IN ARTHRITIS AND RHEUMATISM>>, 2026; 2026 (80:153030): 1-10. [doi:10.1016/j.semarthrit.2026.153030] [https://hdl.handle.net/10807/341404]
Long-term remission and monocyclic course in Still’s disease patients starting canakinumab early: data from the international AIDA Network registry
Rigante, Donato;Verrecchia, Elena;
2026
Abstract
Objectives: To evaluate whether early canakinumab initiation may provide treatment advantages in Still’s disease (SD) patients, particularly in terms of therapy discontinuation due to long-term disease remission, glucocorticoid sparing effect, and increase in the frequency of monocyclic disease course rather than a polycyclic or chronic articular pattern. Methods: SD patients treated with canakinumab were grouped according to time between disease onset and canakinumab initiation (≤3 months vs. >3 months). Patients were enrolled from the international AutoInflammatory Disease Alliance (AIDA) Network registry for SD. Results: Overall, 190 patients were enrolled, 35 (19%) treated with canakinumab within three months from SD onset and 155 (82%) starting canakinumab later. Glucocorticoids use decreased more rapidly in patients receiving canakinumab within 3 months from SD onset than among patients treated later, with reductions of 50% vs 6% at month 3 (p=0.0001), and 75% vs 32% at month 6 (p=0.004). In logistic regression analysis, canakinumab initiation within 3 months from disease onset was significantly associated with treatment discontinuation due to long-term remission (OR 4.83, 95% CI 1.08-23.19; p=0.04). A monocyclic course occurred in 49% of patients starting canakinumab ≤3 months versus 8% starting later (p<0.0001). Starting canakinumab within 3 months from disease onset was significantly associated with a monocyclic disease course compared with the chronic-articular (RRR 4.43, 95% CI 1.12-17.60; p=0.034) and polycyclic courses (RRR 8.97, 95% CI 1.29-62.3; p=0.03). Conclusions: Early canakinumab initiation is associated with treatment discontinuation due to long-term remission and appears linked to a greater frequency of a monocyclic disease course.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
